论文部分内容阅读
目的:探讨不同剂量缩宫素对预防产后出血的临床效果。方法:选择我院2015年2月-2016年4月收治的96例产后出血高危因素产妇,按照给予缩宫素剂量不同分为两组。对照组产妇仅给予20U缩宫素治疗,观察组产妇给予大剂量缩宫素治疗。观察两组产妇发生产后出血的情况,并就两组产妇治疗过程中不良反应发生情况比较。结果:观察组产妇第三产程、产后2h、产后24h出血量均显著低于对照组,差异有统计学意义(P<0.05)。观察组治疗过程中不良反应发生率6.25%与对照组8.33%比较,差异无统计学意义(P>0.05)。结论:针对高危产后出血产妇可行大剂量的缩宫素进行治疗,有效降低产后出血,且不良反应较少,安全性更高,值得临床推广。
Objective: To investigate the clinical effect of different doses of oxytocin on preventing postpartum hemorrhage. Methods: 96 cases of postpartum hemorrhage risk women in our hospital from February 2015 to April 2016 were selected and divided into two groups according to the dose of oxytocin. The control group only given 20U oxytocin treatment, observation group maternal high-dose oxytocin treatment. Observe the situation of postpartum hemorrhage in two groups of maternal and compare the incidence of adverse reactions in the two groups of maternal treatment. Results: In the observation group, the amount of hemorrhage in the third stage of labor, postpartum 2 h, and postpartum 24 h were all significantly lower than those in the control group (P <0.05). The incidence of adverse reactions in the observation group during treatment was 6.25% compared with that of the control group (8.33%), with no significant difference (P> 0.05). Conclusion: The high-risk postpartum hemorrhage maternal high-dose oxytocin for treatment, effective in reducing postpartum hemorrhage, and less adverse reactions, higher safety, worthy of clinical promotion.